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Abstract 
Progress in basic research led to the design of new generations of anticancer drugs with some notable 
achievements. Over the years, more and more powerful drugs have been developed with the purpose 
of increasing the rate of response to therapy. As molecular power of chemotherapeutic agents 
increased, unfortunately also toxicity and undesired side-effects increased as well. The search for 
new therapeutic strategies to be used in the management of cancer is one of the more promising 
strategies to reduce chemotherapy toxicity. Extracorporeal Shock Waves (ESW), widely used for the 
treatment of urolithiasis, have been reported to cause modifications of cell growth both in vitro and 
in vivo. They exert an agonist cytotoxic effect with several chemotherapeutic agents like cisplatin, 
doxorubicin, bleomycin, paclitaxel and, moreover, as it has been reported that their main mechanism 
of action is an increase in cell membrane permeability, ESW are also used to deliver oligonucleotides 
and other small particles to cells. Recently, it has been found that certain dye compounds, in 
particular porphyrins, can achieve a cytopathogenic effect when the disease site is subjected to 
ultrasound irradiation. This technique is referred to as sonodynamic therapy. Based on the new 
knowledge about the interaction between ultrasound with bulk liquid, several studies have shown a 
synergic effect of ESW and porphyrins in vitro, thus opening a new perspective in the sonodynamic 
therapy, able to overcome some drawbacks encountered during conventional anticancer drug 
treatment. Finally, the current advances in bioengineering encouraged the application of nano-scale 
technologies to medicine. Nanobubbles, composed of an external shell and a gas core, can deliver 
chemotropic drugs and porfirins, to tumour target tissues in response to physical triggers, and ESW 
features make them an ideal alternative to ultrasound in combination with drug-loaded nanobubbles 
in delivery strategies.  
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Introduction 
The mainstream of non-invasive therapies for treating solid tumors is by far chemotherapy. Taking 
into account that a crucial prerequisite for any cancer therapy is that the benefits of killing cancer 
cells outweigh deleterious side effects, it is admitted that any chemotherapy scheme is limited by 
both sub-optimal specificity for cancer cells and the probability to induce suppression of the host 
anti-cancer immunity. Over the years, more and more powerful drugs have been developed to 
increase the rate of response to therapy. As molecular power of chemotherapeutic agents increased, 
unfortunately also toxicity and undesired side-effects increased as well. Therefore, the search for 
new therapeutic programs to be used in the management of cancer, like innovative methods to 
deliver drugs to cancer cells, immunotherapy and gene therapy, in addition to the development of 
new pharmaceutical molecules, is one of the more promising strategies to reduce chemotherapy 
toxicity. 
Extracorporeal Shock Waves  
Extracorporeal Shock Waves (ESW) are high-energy acoustic waves produced by a generator 
through the conversion of electrical energy to mechanical energy. They propagate in water medium 
and are characterized by a definite shape with an initial positive, very rapid part of high amplitude, 
followed, after a few microseconds, by a sudden phase of mild negative pressure, before returning to 
the basic values. There are three main techniques through which ESW are generated. These are the 
electrohydraulic, electromagnetic, and piezoelectric principles, each of which represents a different 
technique of generating the shock wave (1,2). 
There are two basic effects of ESW; the primary effect is the direct generation of mechanical forces 
that result in the maximal pulse energy concentrated at the point where treatment is to be provided; 
and the secondary effect is the indirect generation of mechanical forces by cavitation which may 
cause damage to the tissues (1-3). 
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Shockwaves have been used in medicine for many years, particularly in extracorporeal lithotripsy 
(ESWL), which uses focused shockwaves to treat non-invasively patients with stone diseases 
(mostly, urinary stones) (1,2). The excellent results achieved by ESWL stimulated research on the 
applications of focused shockwaves in other branches of medicine. Recent progress in antitumor 
target therapy and delivery systems triggered by physical forces reinforces the use of ESW as a new 
tool to be used in anticancer delivery strategies. The present review highlights the different 
anticancer strategies using ESW: the cytocidal effect of ESW alone or in combination with 
chemoterapic drugs; the sonodynamic therapy; the ESW-aided gene transfer; the nanotechnologies 
(Table 1). 
Cytocidal effect of ESW alone or in combination with chemoterapic drugs 
Cell membranes, which have a thickness of a few molecular layers, are subjected to extremely high 
pressure gradients at the transit of ESW. For this reason, in the late 80s - early 90s, some authors 
took into account to expose a spatially limited region of the body to a potentially destructive form of 
mechanical energy. They hypothesized to take advantage of the cytotoxic/cytocidal effect of ESW, 
until then exclusively used for the treatment of urolithiasis, which could be regarded as an important 
additional support in cancer treatment. Appropriate in vitro and in vivo studies showed that ESW 
could cause only temporary growth delay. Nevertheless, considerable morphological changes at the 
cellular level were observed, including effects on plasma membrane, mitochondria, cytoplasm and 
nucleus (4-6). These damaging effects could sensitize tumor cells to most cytotoxic agents. Further 
studies (7-8) suggested that cell membrane permeabilization is the most prominent alteration induced 
by essentially sublethal doses of High Energy Extracorporeal Shock Waves (HESW). With respect to 
the potential side effects of ESW treatments, permeabilizing ESW energies were observed to induce 
cell mortality in a dose-dependent manner (9). Thus, concurrent treatment regimens with ESW and 
hydrophilic drugs looked promising since ESW can regionally render tissue more susceptible to the 
drug with the prospect of reduced systemic toxicity. ESW were reported to cause modifications of 
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cell growth both in vitro and in vivo (5, 10). Zhou and Guo (11) observed, in nude rats, that high 
energy ESW treatment was able to delay tumor growth and reduce tumor size, without evidence of 
metastasis.  
A substantial difficulty in comparing the results obtained by different Authors is due to the large 
heterogeneity of mechanical, biological and analytical variables in each experimental procedure. In 
vitro studies have shown that ESW treatment elicits immediate reduction of cell viability and ability 
to form colonies (5). Different sensitivities to ESW of different cell lines have been described by 
Brummer et al. (12). Moreover, the impact of ESW on cell survival varies not only with the cell type, 
but also between cell lines of the same type (13); it was hypothesized that cells in G2-M phase cell 
cycle can be more easily damaged by ESW as compared to cells in G0. 
With regard to the mechanism by which ESW cause cellular damage, numerous hypotheses have 
been advanced. Based on the fact that cells did not show any damage when immobilized in agar, 
Brummer et al. (14) suggested that the collision between cells could play a role in changing their 
viability; it was subsequently proven that viability was not influenced by varying cell concentration 
(13). It was also suggested a possible role of free radicals that are generated by Shock Waves in 
inducing cellular damage. Currently, the best hypothesis on the mechanism of cell damage elicited by 
Shock Waves is that of cavitation and the generation of jet streams in the extracellular milieu. The 
cells that survive after ESW exposure are still able to form tumors when inoculated in animal models, 
but these tumors are smaller than in controls (ESW-untreated) since a significant percentage (40 to 
60%) of surviving cells that have been inoculated showed sublethal induced damages (5).  
Numerous studies have shown that the combined treatment of tumor cells in suspension with some 
anticancer agents and ESW elicits a significant enhancement of drug cytotoxic effect (15,16). It was 
noted that Shock Waves, when applied to cells in vitro, determine (even at low energy) a transient 
increase in cell membrane permeability by opening pores, allowing higher concentrations of drug 
enter into the cells (17,18). This effect is similar to that obtained through the technique of 
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electroporation, as direct access to the cytoplasm was also gained by high voltage electric pulses. 
Electroporation was shown to enhance the action of bleomycin and it had been clinically applied to 
subcutaneous tumor nodules (19). It has to be pointed out that a major problem of 
electrochemotherapy is that the electrodes have to be in close local contact over the whole tumor 
surface. This prohibits its use in internal organs. ESW can, in contrast, be directly administered to 
internal organs such as the liver or the gut, and no surgical intervention is necessary. 
Cells of human estrogen-dependent breast cancer (MCF-7) were sensitive to combined treatment with 
ESW and paclitaxel, an antimicrotubule agent, active against a variety of solid tumors (9). The 
suppression of cell proliferation induced by Shock Waves has been related to an apoptotic mechanism 
(16). Apoptosis, i.e. programmed cell death, is a cellular self-destruction mechanism, which plays a 
key role in the surveillance against tumors (20). Induction of apoptosis occurs in response to a variety 
of stress signals (21) which may include Shock Waves (16). 
Recent studies have shown the cytotoxic action enhanced by Shock Waves in combination with some 
anticancer drugs in vitro: cell lines of human osteosarcoma (22), human colorectal adenocarcinoma 
(23) and human anaplastic thyroid cancer (24) were subjected to combined treatment (ESW and 
anticancer drugs).  Combined exposure to anticancer drugs and Shock Waves resulted in a significant 
enhancement of cytotoxicity and induction of apoptosis in cancer cells.  
Sonodynamic/photodynamic properties of ESW 
In the work by Catalano et al. (24) an innovative "sonodynamic/photodynamic" technique was 
adopted, based on ability of ESW to activate and render cytotoxic a photosensitizing substance: the 
natural porphyrin precursor 5-aminolevulinic acid (ALA), which is accumulated selectively by 
neoplastic cells.  
In normal cells, protoporphyrin IX (PPIX), a substance with excellent photosensitizing properties, 
does not accumulate to a great extent because it is quickly transformed to heme by the action of 
ferrochelatase. In cancer cells, however, PPIX accumulates due to a defective heme biosynthesis, as 
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a consequence of abnormal levels of some enzymes involved in this pathway. Increased activity of 
porphobilinogen deaminase and/or decreased activity of ferrochelatase have been reported for a 
number of tumors. Exogenous application of ALA can lead to a pronounced accumulation of PPIX in 
tumor tissue and subsequent irradiation with light of wave lengths (corresponding to the PPIX 
absorption bands) can lead to specific destruction of tumor cells. Photodynamic therapy (PDT) has 
developed as an important new clinical cancer treatment modality in the past 25 years but the low 
penetration depth of light through the skin and tissues has limited PDT to the treatment of superficial, 
endoscopically reachable tumors. The main assumption about “sonodynamic” therapy is to generate 
ultrasound energy which produces sonoluminescence to excite the protoporphyrin derivative by 
energy transfer. HESW induce acoustic cavitation, which results in a concentration of energy 
sufficient to generate a sonoluminescence emission, able to cause electronic excitation of porphyrins 
and initiate a photochemical process resulting in the formation of the cytotoxic singlet oxygen (25). 
The mechanisms underlying this effect were explained on the basis of double basic effect elicited by 
HESW treatment: the direct generation of mechanical forces (non-inertial cavitation) and the indirect 
generation of mechanical forces by cavitation (inertial cavitation). Non-inertial cavitation bubbles 
oscillate and cause streaming of the surrounding liquid and mechanical stresses. Inertial cavitation is 
an extremely violent process of bubble activity that may generate highly reactive hydroxyl radical. 
The subsequent energy transfer to oxygen can generate the highly reactive singlet molecular oxygen 
(25). This combination between inertial and non-inertial cavitation, generated by a piezoelectric 
Shockwave device, was confirmed by Canaparo et al. (23), who observed  that combined ALA-high 
energy ESW treatment produced significant inhibition of HT-29 (human colorectal carcinoma) cell 
growth. Non-inertial as well as inertial cavitation was seen to induce apoptosis as well as to inhibit 
cell growth by increasing the G0/G1 population through the intracellular activation of protoporphyrin 
IX. 
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 “Sonodynamic therapy” is an analogous approach to PDT based on the synergistic effect of 
ultrasound and chemical compound referred to as "sonosensitizer", but the attractive feature of this 
modality for cancer treatment emerges from the ability to focus the ultrasound energy on malignancy 
sites deeply placed in tissues. The ESW source can be placed at direct contact with the body and the 
maximum energy flow given to the inner part of the tumor can be precisely controlled. Nonetheless, 
at transition sites between tissues with different acoustic impedance values, there may be focal 
mechanical destruction, probably through the induction of cavitation and shearing stress caused by 
the reflected waves (26). 
This technique has proven to be effective in vivo, by inducing necrosis and apoptosis of breast cancer 
and colon cancer implanted in laboratory animals (27,28).  
Most recently, the anticancer effect of Sonodynamic therapy (SDT) using ESW-activated 
protoporphyrin IX cytoxicyty on a syngeneic rat breast cancer model was confirmed by magnetic 
resonance imaging (MRI). The SDT-treated group showed a significant decrease in MRI tumor size 
measurements 72 hours after treatment with the PPIX precursor ALA and ESW (29). 
Nano-scale technology and ESW 
The current advances in material science and bioengineering encouraged the application of nano-
scale technologies to medicine; nanocarriers (or nano-encapsulation systems) have been introduced 
as promising vehicles in drug delivery. In such systems, drugs and bio-active agents are wrapped in 
or adsorbed on the surface of nanoparticles in order to achieve safe and effective drug delivery and 
gene therapy (30). When compared to traditional delivery systems, nanocarriers used in 
chemotherapy have higher therapeutic efficiency at low dosage and can accumulate preferentially in 
the desired locations due to the defective vascular architecture of most solid tumors. This enables the 
nanocarriers circulating in the blood to be entrapped inside the leaky vessels of the tumor, thus 
slowly releasing their contents. In recent years, a wide range of nanoparticles (NPs) have been 
employed as drug-delivery carriers for cancer therapy. NPs can carry loaded drugs to the tumor site 
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through the blood stream taking advantage of the enhanced permeability and retention effect, due to 
the defective vascular architecture of the tumor tissue (31). Actually, growing attention in the field of 
nanomedicine has been given to micro- and nanobubbles (NBs). NBs, composed of an external shell 
and a gas core, can deliver diverse molecules, such as DNA and drugs, to target tissues in response to 
physical triggers, like ultrasound. Based on their features, ESW may be considered an ideal 
alternative to ultrasound in combination with drug-loaded NBs in delivery strategies. We recently 
demonstrated that combining new doxorubicin-loaded glycol chitosan NBs and ESW enhanced 
doxorubicin anti-tumor activity in anaplastic thyroid cancer cell lines, by increasing intracellular 
drug release (32).  
Moreover, nanoparticles may enhance the sonodynamic therapy response by playing different roles: 
if properly engineered, the sonosensitizer agent loaded onto NPs, can pass more readily across the 
cell membrane, reaching its critical intracellular target. It has been demonstrated that sonosensitizers 
loaded onto NPs are more readily taken up by cells with respect to the free drug (41).  Moreover, 
NPs are able not only to function as a sonosensitizer per se, but also as energy transducers (33). The 
synthetic water-soluble TPPS [meso-tetrakis (4-sulfonatophenyl) porphyrin] has been widely 
investigated as a photosensitizer because of its high tumor tissue affinity and retention rate, as well 
as a remarkable quantum yield of singlet oxygen formation in solution (34). 
Quite recently, an innovative sonosensitizing system using ESW and a new formulation of 
nanoparticles [poly-methyl methacrylate core-shell nanoparticles (NPs)] loaded with TPPS has been 
described (35). The sonodynamic treatment with nanoparticles loaded with porphyrin derivative 
(TPPS-NPs) and ESW was investigated with regard to cytotoxic effect on the human neuroblastoma 
cell line, SH-SY5Y. Single cell treatments, such as exposure to ESW alone or TPPS alone, had no 
effect on SH-SY5Y cell proliferation. Indeed, the combined treatment with TPPS-NPs and ESW, 
showed a statistically significant decrease in SH-SY5Y cell proliferation. This new sonosensitizing 
system significantly decreased cancer cell growth after ESW exposure, even in a three-dimensional 
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model of neuroblastoma, suggesting its potential further application in sonodynamic anticancer 
therapy (35,36). 
Cancer gene therapy and ESW-aided gene transfer 
Cancer gene therapy has made important progresses. One established immunotherapy approach 
involves enhancement of the immune response against cancer through the augmentation of natural 
cytokines. These proteins can either be repeatedly injected or produced by plasmid DNA transfer and 
protein expression in cells of the tumor or host animal. Immunogenic therapy using pIL-12 has 
shown promise in some immunogenic mouse tumor models (37). However, systemic application is 
problematic, since effective IL-12 doses are toxic to the animal. Thus, the search for new delivery 
methods remains of great interest, particularly for established tumors. Physical methods for 
membrane permeation, along with their ability to promote cell transfection, may overcome the 
barriers of gene transfer using non-viral vectors. These methods include electroporation, direct 
injection, biolistic particle delivery, laser irradiation, magnetic nanoparticles and acoustic cavitation. 
Because of their adaptability to in vivo purposes (easy to use, minimal effects on normal physiology), 
electroporation and acoustic cavitation seem to be the most promising techniques for gene therapy 
applications. In particular, the utility of acoustic cavitation for cell permeation and transfection has 
been illustrated in different cell types, both in vitro and in vivo (38,39). 
In the last decade some studies showed that Shock Waves can support transfection, i.e. the transfer of 
therapeutic genes to targets by temporarily increasing cell membrane permeability: DNA - or 
fragments, such as plasmids - can enter the cell (18,37,38,40). The combination of shock waves and 
DNA cationization for cell transfection was explored on an in vitro model of suspended cells and 
GFP (green fluorescent protein) reporter-containing plasmid DNA (41). In terms of percentages of 
transfected cells, the efficiencies found were comparable to those reported by other acoustic 
cavitation-based approaches (42).  
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ESW-aided gene transfer has been associated with many advantages in cancer gene therapy: 1) 
localization of DNA transfer to the tumor; 2) cavitation-induced cell killing resulting in tumor 
ablation, and, 3) the avoidance of antigenic responses associated with virus-based DNA delivery 
methods (43,44). Quite recently a synergistic approach has been described using ultrasound and 
nanoparticles to deliver plasmid DNA to cancer cells, achieving really high transfection efficiency 
and enhanced the antitumor effect (45). With regard to Shock Waves, the use of the latter has just 
been confirmed to permeabilize human cells and promote transfection with both cationic lipid-
assembled and naked DNA (41).  
Advantages, Limitations and Concluding Remarks  
The studies described above suggest that Shock Waves are a promising anticancer strategy for in 
vivo applications since tissues located at different depths in the body can be readily targeted by 
extracorporeal treatment, with minimal histopathological damage. The ESW generator can be easily 
placed in contact with a water-based gel on the skin and ESW can be focused at the tumor site, thus 
potentially permitting to target tumor lesions. Finally, unlike ultrasound, ESW have not heating 
effects. This could be an advantage for in vivo application since temperature elevation is difficult to 
control spatially and temporally, especially in large tumors with heterogeneous vascularization. 
Unfortunately, the biggest limitation in the use of ESW in cancer therapy is that, in front of the huge 
amount of pre-clinical data, solid clinical trials are missing. In fact, to date, only one “old” case 
report combined ESW and chemotherapy to treat metastasis of prostate cancer in the iliac muscle 
(46), and, very recently, long-term effectiveness of ESW has been demonstrated for the treatment of 
lymphedema in patients with breast cancer (47).    
Nevertheless, based on their multifaceted properties, the use of ESW in oncology looks promising. In 
fact: 1) ESW act as an "ultrasound-susceptibility modification agent“ since they may induce cell 
permeabilization, thus allowing better delivery of chemotherapeutic drugs into cytosol; 2)  Shock 
Waves enhance both the cytotoxic activities of photosensitizers as well as the apoptotic signal 
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transduction pathway: they can act as a further tool in “sonodynamic/photodynamic” therapy; 3) 
Gene transfer can be induced by ESW treatment in vivo, particularly with enhanced acoustic 
cavitation, which supports the concept that “Gene and ESW therapy might be advantageously 
merged”; 4) Other treatment schedules are worth to be explored to evaluate the potential utility of 
ESW in cancer therapy, especially in combination with other modalities. 
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Table 1. Different anticancer strategies using combination therapy with ESW. 
 
 
 
Anticancer  Strategies 
 
Drugs Models References 
Cytocidal effect of ESW 
- 
In vitro 
In vivo 
4, 6, 7, 13 
10, 11 
ESW and chemotherapic 
drugs 
mitomycin C; cisplatin; 
methotrexate; adriamycin; 
paclitaxel; daunorubicin; 
bleomycin; 5-fluouracil 
In vitro 
 
In vivo 
8, 9, 15, 22 
 
16, 17 
Sonodynamic Therapy 5’-aminolevulinic acid (ALA) In vitro 
In vivo 
23, 24 
27-29 
Gene Transfer DNA plasmids; interleukin-12 In vitro 
In vivo 
43, 44   
39, 44 
Nanoparticles doxorubicin; meso-tetrakis (4-
sulfonatophenyl) porphyrin 
(TPPS) 
In vitro 
In vivo 
32 
35, 36 
